Injection dynapar aq
Reading File
Finding Sources
Searching the Web
Dynapar AQ injection diclofenac sodium uses dosage
Reading File
Reading File
I now have comprehensive information. Here is a full clinical profile of Injection Dynapar AQ:
Injection Dynapar AQ (Diclofenac Sodium)
What is it?
Dynapar AQ is the brand name for diclofenac sodium injection (aqueous formulation), available as 75 mg/3 mL (25 mg/mL). It is a non-selective NSAID belonging to the phenylacetic acid (acetic acid derivative) group. The "AQ" (aqueous) formulation differs from older diclofenac injections that used organic solvents (benzyl alcohol, PEG), making Dynapar AQ better tolerated at the injection site.
Mechanism of Action
Diclofenac inhibits both COX-1 and COX-2 enzymes, reducing prostaglandin synthesis. It has a unique pharmacokinetic behavior:
- At peak plasma levels - inhibits both COX-1 and COX-2
- As plasma levels fall - behaves more like a selective COX-2 inhibitor
- It accumulates in synovial fluid, giving it a longer duration of action than its short plasma half-life suggests
- (Goodman & Gilman's Pharmacological Basis of Therapeutics)
Pharmacokinetics
| Parameter | Value |
|---|---|
| Onset (IM) | 15-30 minutes |
| Peak effect | 30-60 minutes |
| Plasma half-life | 1-2 hours |
| Protein binding | >99% |
| Bioavailability (oral) | ~50% (first-pass effect); injection bypasses this |
| Metabolism | Liver, primarily CYP2C9 -> 4-hydroxydiclofenac |
| Excretion | Urine 65%, bile/feces 35% |
Indications (Therapeutic Uses)
- Renal colic (very effective, comparable to opioids)
- Acute post-operative pain
- Acute musculoskeletal pain - back pain, sprains, fractures
- Exacerbations of osteoarthritis and rheumatoid arthritis
- Acute gout
- Acute trauma
- Primary dysmenorrhea
- Peri-operative pain management
Dosage and Administration
| Route | Dose | Frequency | Max Daily Dose |
|---|---|---|---|
| IM (deep gluteal) | 75 mg | Once or twice daily | 150 mg/day |
| IV infusion | 25-50 mg loading, then ~5 mg/hr | Continuous | 150 mg/day |
| IV bolus | 37.5 mg | Every 6 hours | 150 mg/day |
- Given by deep intramuscular injection into the upper outer quadrant of the gluteus or lateral thigh
- IV route requires dilution in normal saline or dextrose
- Parenteral therapy should not exceed 2 days - switch to oral once possible
- Not recommended in children
Contraindications
- Active peptic ulcer / GI bleeding
- Hypersensitivity to diclofenac or any NSAID
- Aspirin-sensitive asthma (NSAID triad)
- Severe renal or hepatic impairment
- Severe heart failure
- Peri-operative CABG surgery (increases cardiovascular risk)
- Pregnancy (especially 3rd trimester - premature closure of ductus arteriosus)
- Hypovolemia / dehydration
Adverse Effects
| System | Effect |
|---|---|
| GI | Nausea, vomiting, epigastric pain, peptic ulceration, GI bleeding (~20% of users) |
| Hepatic | Elevated transaminases in ~4%; severe liver injury in 6-11 per 100,000 users/year |
| Cardiovascular | Hypertension, edema, increased MI and stroke risk |
| Renal | Fluid retention, renal impairment, hyperkalemia |
| CNS | Headache, dizziness |
| Local (injection site) | Pain, induration - reduced with AQ formulation |
| Hypersensitivity | Rash, bronchospasm |
Monitor LFTs during first 8 weeks of therapy.
Important Drug Interactions
- Anticoagulants (warfarin) - increased bleeding risk
- Antihypertensives / diuretics - reduced efficacy, renal risk
- Methotrexate - decreased methotrexate clearance, toxicity risk
- Lithium - increased lithium levels
- Cyclosporine - increased nephrotoxicity
- Other NSAIDs / aspirin - additive GI toxicity; avoid combination
- Finerenone (CYP3A4) - monitor potassium
Special Precautions
- Elderly: use lowest effective dose; higher risk of GI and renal adverse effects
- Renal/hepatic impairment: use with caution, reduce dose
- Cardiovascular disease: increased MI/stroke risk; shortest duration, lowest dose
- GI risk: consider co-prescribing a PPI (e.g., omeprazole) for patients at risk
- Hepatotoxicity monitoring: LFTs at 8 weeks if on repeated dosing
- Not recommended in nursing mothers or pregnant women
Why AQ (Aqueous) Formulation?
Traditional diclofenac injections contained organic solvents (benzyl alcohol, propylene glycol, PEG) which caused significant injection-site pain and tissue necrosis. Dynapar AQ uses an aqueous (water-based) buffered formulation - this dramatically reduces:
- Local injection site pain
- Tissue irritation and induration
- Risk of sterile abscess formation
Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics | StatPearls - Diclofenac | TMDA Product Monograph
Fever
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Injection dynapar aq can cure fever
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Here is a clear, evidence-based answer:
Can Injection Dynapar AQ Cure Fever?
Short Answer: Partially yes - it can reduce fever, but it does NOT cure the underlying cause.
What Dynapar AQ (Diclofenac) Does to Fever
Diclofenac is an NSAID. All NSAIDs share three actions:
- Anti-inflammatory
- Analgesic (pain relief)
- Antipyretic (fever reduction)
The antipyretic mechanism works as follows:
Pyrogens (e.g., IL-1 from macrophages) stimulate the hypothalamus to produce prostaglandin E2 (PGE2), which raises the temperature set-point. Diclofenac inhibits COX enzymes, blocking PGE2 synthesis, thereby lowering the hypothalamic set-point back to normal.
So yes - diclofenac can reduce body temperature in a febrile patient.
- Goodman & Gilman's Pharmacological Basis of Therapeutics
Why It is NOT the Drug of Choice for Fever
| Feature | Dynapar AQ (Diclofenac) | Paracetamol (1st choice) |
|---|---|---|
| Primary indication | Pain, inflammation | Fever + mild pain |
| Antipyretic potency | Moderate | High |
| GI safety | Poor (peptic ulcer risk) | Excellent |
| Route for fever | IM injection (invasive) | Oral / IV (simple) |
| Approved for fever | Not specifically licensed | Yes |
| Safe in children | No | Yes |
| Safe in pregnancy | No | Yes (1st & 2nd trimester) |
| Renal risk | Yes | Minimal at therapeutic doses |
Important Distinction: Reducing Fever vs. Curing Fever
- Dynapar AQ lowers temperature symptomatically - it treats the symptom, not the cause
- Fever is a symptom, not a disease. The underlying cause (infection, autoimmune disease, malignancy) needs separate, specific treatment
- For example: a bacterial infection causing fever needs antibiotics - diclofenac alone will not cure it
- Antipyretics of any kind only manage fever, never cure it
When Diclofenac Injection May Be Used in a Febrile Setting
It is sometimes used in clinical practice when fever is accompanied by:
- Significant musculoskeletal pain or joint pain (e.g., fever in gout, arthritis flare)
- Post-operative fever with pain
- Renal colic with associated fever
In these cases, it addresses both the pain and partially the fever.
Bottom Line
| Statement | Verdict |
|---|---|
| "Dynapar AQ reduces fever" | True - via COX inhibition reducing PGE2 |
| "Dynapar AQ cures fever" | False - it only suppresses the symptom |
| "Dynapar AQ is the best drug for fever" | False - paracetamol is first-line |
| "Dynapar AQ treats the cause of fever" | False - cause must be treated separately |
For routine fever management, paracetamol (oral or IV) remains the drug of choice due to superior safety, simpler administration, and specific antipyretic licensing. Dynapar AQ should not be used as a primary antipyretic, especially in children, pregnant women, or patients with GI or renal risk.
This is a shared conversation. Sign in to Orris to start your own chat.